Építés alatt – nem éles oldal
Belépés
Taking people in KanadaNo phase

Personalized B-fructan Diet in Inflammatory Bowel Disease Patients

Key facts

Where
Edmonton és Winnipeg, KanadaSee the 2 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 39 years old?

Forrás: NCT05615779: ki vehet részt

Where in Kanada

  • University of Alberta HospitalEdmonton, KanadaTaking people
  • Health Sciences Centre HospitalWinnipeg, KanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University of Manitoba
Trial code
NCT05615779
Record updated
2025. április 6.
Original description
This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.Read full original descriptionShow less

The Fibre Study: RCT of Personalized Fibre Diet in IBD

This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.

Inclusion: Children (age 6-17) or young adults (age 18-39); Known or suspected UC or IBDU [there will be 2 control group: non-IBD (undergoing colonoscopy but found not to have IBD; and healthy (no GI symptoms, so not required to have colonoscopy; could be family members)]; For UC: Remission-mild-moderate disease: Mayo score <10; Clinical indication for sedated colonoscopy; Disease location: E2-E4; Stable treatment (not on steroids; biologics or immunomodulator not changed in last month); High likelihood that patients will be able to collect all samples and provide all data.

Exclusion: Documented enteric infection during the 3 months prior to endoscopy; Systemic steroids (above 10 mg/day of Prednisone); Topical therapy within 1 week of endoscopy; History of abdominal surgery, including appendectomy; Presence of non-IBD bowel conditions (e.g., celiac), anatomical or mucosal abnormalities, motility disorder; Presence of a systemic disease requiring treatment (cancer, ischemic heart disease, kidney failure, etc); Use of antibiotics for a week or more over the last 3 months; Use of probiotics or prebiotics at pharmacological doses (adding fibre sources to food or probiotics in yogurt, for example, are allowed); Proctitis (E1); Recent change in IBD treatment (started biologics or IM over the last month); Pregnancy or planning to become pregnant during the study; Inability to understand or sign the consent.

ClinicalTrials.gov NCT05615779